SKIN AND COAT CARE

OCUVIR 800 DT TABLET

OCUVIR 800 DT TABLET

By FDC

Regular price ₹ 210.89
Sale price ₹ 210.89 Regular price M.R.P:
Enquire Now
Tax included. Shipping calculated at checkout.
Pack - 5Tabs
Expires on or after: Feb, 2027

Best deal on the Internet

Prescription Required question

Title

Check Availability

Rapid 3-4 Day Delivery,Tiny Extra Fee!

  • AnimealPet Safe
  • AnimealBest Quality
  • AnimealFast Delivery
  • AnimealSecure Payment
View full details

Collapsible content

About Product

Ocuvir 800 DT Tablet by FDC Limited is a prescription-only, high-strength dispersible antiviral formulation containing Acyclovir 800mg, engineered to target serious herpesvirus infections in companion animals. It addresses clinically significant viral conditions caused by alpha-herpesviruses, including herpes simplex virus infections, herpes zoster (shingles), and varicella-zoster virus (chickenpox), by disrupting viral DNA replication at the intracellular level and halting the propagation of infection through host tissue. The dispersible tablet format ensures flexible, precise administration, particularly important in veterinary contexts where swallowing intact tablets may be challenging and where dose titration is critical. In veterinary medicine, Acyclovir has been used in the management of canine herpesvirus-1 infections and, under strict veterinary supervision with careful species-specific caution, as part of antiviral management protocols in select cases. Animeal is proud to offer Ocuvir 800 DT Tablet as part of its curated prescription pharmaceutical range, supporting informed, responsible antiviral care for your companion animal.

Ingredients:

Acyclovir 800mg per dispersible tablet:

Acyclovir is a synthetic acyclic purine nucleoside analogue of deoxyguanosine, the naturally occurring nucleoside building block of DNA. Its antiviral action is exquisitely selective and depends on a multi-step phosphorylation cascade that is initiated almost exclusively in virus-infected cells. Upon entering a herpesvirus-infected cell, acyclovir is first phosphorylated to acyclovir monophosphate by viral thymidine kinase (TK), an enzyme expressed specifically by herpesvirus-infected cells and virtually absent in uninfected host cells. This first phosphorylation step is the critical selectivity gate that concentrates the drug's activity in infected cells while largely sparing healthy tissue. Host cellular kinases then convert acyclovir monophosphate sequentially to acyclovir diphosphate and finally to the active triphosphate form, acyclovir triphosphate. Acyclovir triphosphate competitively inhibits viral DNA polymerase with approximately 30 to 50 times greater affinity than it inhibits mammalian cellular DNA polymerase, thereby achieving targeted viral suppression. Additionally, when acyclovir triphosphate is incorporated into the growing viral DNA chain in place of deoxyguanosine triphosphate, it acts as an obligate chain terminator: the absence of a 3-prime hydroxyl group on its acyclic sugar moiety prevents further elongation of the DNA strand, permanently halting viral genome replication. This dual action of competitive enzyme inhibition and irreversible DNA chain termination makes acyclovir a potent and highly selective antiviral agent against susceptible herpesviruses.

 

Features and Benefits

Targeted Viral DNA Replication Suppression: Ocu...

Targeted Viral DNA Replication Suppression:
Ocuvir 800 DT targets herpesvirus replication at the cellular level by exploiting the virus's own thymidine kinase enzyme to convert acyclovir into its active antiviral form selectively within infected cells. This precision-targeted activation sharply limits activity in uninfected host tissue, delivering powerful antiviral effect where it is needed most while preserving your companion animal's healthy cells.

Reduced Severity and Duration of Herpetic Outbreaks:
By halting viral DNA chain elongation and blocking further viral spread, Ocuvir 800 DT alleviates the painful, ulcerative, and vesicular lesions associated with herpes simplex and herpes zoster infections, including cold sores, genital sores, and shingles rashes. Consistent, timely administration reduces both the intensity and the duration of active outbreaks, supporting faster healing and meaningful relief from pain, itching, and discomfort.

Prevention of Viral Dissemination and Reactivation:
Ocuvir 800 DT restricts the spread of actively replicating virus through surrounding tissue, lowering the overall viral burden and reducing the risk of disseminated herpetic disease in immunocompromised patients. Long-term suppressive use, where prescribed by a veterinarian, can reduce the frequency of recurrent reactivation episodes in susceptible animals, providing a sustained shield against the cyclical flare pattern characteristic of latent herpesvirus infections.

Dispersible Tablet Format for Flexible Veterinary Administration:
The DT (dispersible tablet) formulation of Ocuvir 800 allows the tablet to be dissolved in water prior to administration, providing significantly greater flexibility in dosing for companion animals compared to standard film-coated tablets. This dispersibility facilitates more accurate dose measurement, easier syringe-based oral administration for resistant patients, and improved palatability, making the treatment course more manageable for both the pet parent and the companion animal.

High-Dose Formulation for Serious Viral Conditions:
At 800mg per tablet, Ocuvir 800 DT delivers a high-concentration dose of acyclovir specifically suited for the management of more severe and acute herpetic conditions, including shingles and primary herpes zoster infections, where higher antiviral loading is required to achieve effective viral suppression. This makes it a clinically appropriate option for serious acute presentations when prescribed within a structured veterinary antiviral treatment plan.

Usage and Applications

How to Use:Ocuvir 800 DT Tablet is a prescripti...

How to Use:

Ocuvir 800 DT Tablet is a prescription medication and must be administered only under the explicit direction and supervision of a qualified veterinarian, who will determine the appropriate dose, frequency, and duration of therapy based on the species, body weight, clinical condition, and immune status of your companion animal. The dispersible tablet should be dissolved in an appropriate quantity of water as directed by your veterinarian before administration, and should never be crushed and given dry or swallowed whole without dissolution, as the dispersible formulation is specifically designed for dissolution prior to use. It may be given with or without food, though administering it at consistent, regular intervals is strongly recommended to maintain effective plasma concentrations across the dosing schedule. Adequate hydration is critically important throughout the course of treatment, as acyclovir is renally excreted and insufficient fluid intake can elevate plasma drug concentrations and increase the risk of renal crystallisation and associated kidney injury. Never double a missed dose; if a dose is missed, administer it as soon as it is recalled unless the next dose is imminent. Do not discontinue the course of treatment early, even if the animal appears to be improving, as premature cessation may allow viral rebound. For any use in cats, strict veterinary authorisation and close monitoring are mandatory given species-specific safety considerations.

Storage Advice:

Store unopened Ocuvir 800 DT Tablet in a cool, dry place below 25 degrees C away from direct sunlight. Do not freeze. Once opened, keep the strip in its original blister packaging and reseal carefully after each use to protect the remaining tablets from moisture and humidity. Once dissolved in water, the solution should be administered immediately and must not be stored for later use. Keep out of reach of children and pets at all times. Do not use after the best-before date printed on the blister strip or carton.

About the Brand:

Founded in 1936 by the late Mr. Anand Chandavarkar as a partnership firm in Mumbai, FDC Limited was formally incorporated as a private limited company in 1940 and has since grown into one of India's top 25 fully integrated pharmaceutical companies, earning accreditations from the US-FDA, UK-MHRA, WHO-GMP, MCC (South Africa), ANVISA (Brazil), and the UAE regulatory authorities across its multi-location manufacturing facilities in Maharashtra, Goa, and Himachal Pradesh. FDC is a recognised pioneer in Oral Rehydration Solutions and ophthalmic therapies in India, and has a particularly distinguished history in antiviral pharmaceutical development, including the proprietary development of Ocuvir SR, an extended-release acyclovir formulation for herpes zoster in immunocompetent patients that earned FDC the PHARMEXCIL Certificate of Appreciation Patent Award. FDC's enduring philosophy of delivering accessible, high-quality, innovation-driven healthcare solutions to patients across the globe, backed by in-house R&D centres recognised by India's Department of Science and Technology, aligns with Animeal's commitment to offering trusted, clinically validated pharmaceutical solutions for your companion animal's health and wellbeing. Discover FDC Limited today.

Disclaimer:

Please note that while Ocuvir 800 DT Tablet is formulated from acyclovir 800mg and is appropriate for veterinary use in select species and presentations, it is a prescription-only pharmaceutical and must not be administered to any companion animal without prior veterinary examination, diagnosis, and a written prescription. It is a complementary antiviral therapeutic agent and is not a substitute for comprehensive diagnostic workup, immune status assessment, or ongoing clinical monitoring by a qualified veterinarian. Systemic oral acyclovir is contraindicated in cats due to the risk of bone marrow suppression and its low bioavailability in this species; only a veterinarian can determine if any form of acyclovir is appropriate for a feline patient. For companion animals with pre-existing kidney disease, dehydration, compromised immune function, or concurrent use of nephrotoxic medications such as tenofovir or cidofovir, consult your veterinarian before introducing this product. Animeal supports your pet's health and happiness journey but does not replace the advice of a qualified veterinary professional.

Frequently Asked Questions

Is Ocuvir 800 DT Tablet suitable for all companion animals?

Ocuvir 800 DT Tablet containing acyclovir 800mg is most commonly used in dogs, particularly for the management of canine herpesvirus-1 infections in puppies, and must be prescribed by a veterinarian for any animal use. It is not recommended for systemic oral use in cats, as acyclovir has low bioavailability in this species and carries a risk of serious bone marrow suppression at therapeutic doses; feline herpesvirus-1 infections are also known to have low susceptibility to acyclovir relative to human herpesviruses. Breed, age, body weight, immune status, and kidney function must all be evaluated by a veterinarian before this product is prescribed.

How often should Ocuvir 800 DT Tablet be administered?

Dosing frequency for Ocuvir 800 DT in veterinary patients is determined entirely by the prescribing veterinarian based on the specific herpesvirus condition being treated, the severity of infection, and the individual patient's clinical profile. In human medicine, the 800mg dosage is typically prescribed five times daily at four-hour intervals for conditions such as shingles, but veterinary dosing schedules may differ significantly and must never be extrapolated from human prescribing guidelines without direct veterinary authorisation. Adequate hydration must be maintained throughout every dosing interval.

How effective is Ocuvir 800 DT for managing herpesvirus infections?

Acyclovir, the active ingredient in Ocuvir 800 DT, is a clinically well-established antiviral agent with decades of use against susceptible alpha-herpesviruses, delivering meaningful reductions in outbreak severity, lesion healing time, pain, and viral shedding when initiated promptly and used consistently as prescribed. In canine herpesvirus-1 infections, it offers an antiviral mechanism that targets viral DNA replication directly, supporting faster clinical resolution under veterinary care. Its effectiveness is most pronounced when treatment begins early in the course of the outbreak, and it does not eliminate latent viral reservoirs but can significantly reduce the frequency and intensity of recurrent episodes with suppressive use.

What are the potential side effects of Ocuvir 800 DT Tablet in companion animals?

Common side effects associated with acyclovir include nausea, vomiting, diarrhoea, headache-equivalent neurological signs, and fatigue. The most clinically significant concern in veterinary patients is renal toxicity: acyclovir can crystallise in the renal tubules if fluid intake is insufficient, leading to reduced kidney function or, in severe cases, renal failure, making adequate hydration throughout the treatment course non-negotiable. In cats, systemic oral acyclovir carries a well-documented risk of bone marrow suppression, which can be life-threatening; this species-specific toxicity requires absolute veterinary oversight for any proposed feline use. If your companion animal displays significant lethargy, vomiting, changes in urination, or neurological signs during treatment, contact your veterinarian immediately.

What makes Ocuvir 800 DT different from standard acyclovir tablets on the market?

Ocuvir 800 DT is a dispersible tablet formulation, distinguishing it from standard film-coated or plain acyclovir tablets in a clinically meaningful way for veterinary use: the tablet dissolves fully in water before administration, enabling precise dose measurement, flexible syringe-based oral dosing for animals that resist tablet administration, and potentially improved drug distribution uniformity in solution compared to a tablet that must dissolve in the gastrointestinal tract. At 800mg per tablet, Ocuvir 800 DT also delivers the highest standard acyclovir oral dose, making it specifically suited for high-burden acute herpetic conditions such as shingles and primary herpes zoster where lower-strength formulations would require multiple tablets per dose and are therefore less practical for the treatment schedule.